

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
2877

In Re Application Of: **OBENDORF**

Serial No.
10/791,017

Filing Date
03/02/2004

Examiner

Group Art Unit

Title: **METHODS FOR DETERMINING HORMONAL EFFECT OF SUBSTANCES**



Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
2877

In Re Application: **OBENDORF**

Serial No.
10/791,017

Filing Date
03/02/2004

Examiner

Group Art Unit

METHODS FOR DETERMINING HORMONAL EFFECT OF SUBSTANCES



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account as described below.
- ☐ Charge the amount of _____
 - ☐ Credit any overpayment.
 - ☐ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on **APRIL 19, 2004** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

MICHAEL J. STRIKER


Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: **APRIL 19, 2004**

CC:



UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:.

Group:

Attorney Docket # 2877

Applicant(s): OBENDORF, M., ET AL

Serial No.: 10/791,017

Filed: 03/02/2004

For : METHODS FOR DETERMINING HORMONAL EFFECT
OF SUBSTANCES

INFORMATION DISCLOSURE STATEMENT

April 16, 2004

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

S I R S:

- ☐ In accordance with the Duty of Disclosure, Applicant(s) submit(s) herewith a copy of a Foreign Search Report in a counterpart application and copies of the reference(s) indicated therein.
- ☐ In the event that the Foreign Search Report is in a foreign language, a translation thereof is herewith submitted.
- ☒ Attached hereto is a FORM PTO 1449 listing the references.
- ☒ Attached hereto is a copy of a reference cited in the specification of the application as filed. The specification itself recites the relevance of these documents, and pursuant to M.P.E.P. Section 609 A (3) this represents an acceptable Statement of Relevancy. The reference(s) appear(s) at the following page(s) and line(s) of the specification: page 5 lines 16-17, page 6 lines 6-7, 9-10, 20-23, page 7 lines 1-5, 20-21, page 8 lines 1-2, 17-18, page 9, line 2.
- ☐ Applicant petitions for consideration of this Information Disclosure Statement since it is being submitted after receipt of an office action. It is respectfully requested that the required fee be charged to the account of the undersigned: 19-4675.

page 2 of 2


- ☒ Attached hereto are copies of references cited which may be pertinent to this application. Since the references are in the English language, no statement of relevancy is submitted.
- ☐ Attached hereto is a copy of the Office Action issued in the corresponding German and European applications, together with a translation thereof and copies of the references cited therein. A list of the cited references is also attached.
- ☐ Attached hereto copies of references cited which may be pertinent to this application. A Certified English translation of the reference is also attached.
- ☐ Attached hereto is a Statement of Relevancy and copies of references cited therein.
- ☐ Relevancy is indicated in an English language abstract attached hereto.

Respectfully submitted,


Michael J. Striker
Attorney for Applicant(s)
Reg. No. 27233

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

2877

Application Number

10/791,017

Applicant(s)

OBENDORF

Filing Date

03/02/2004

Group Art Unit

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
		99/50664	10/07/1999	WO				
							✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		DATABANK PUBMED BEI NCBI, ADRESSE WWW.NCBI.NLM.NIH.GOV, ZUSAMMENFASSUNG ZU: THOMAS ET AL: THE PRO-ONCOPROTEIN..., IN CANCER BIOL. THER (2002) 1 (4), 428-32.
		VISHWANTH BUDHRAM-MAHASEO, ET AL: "POU TRANSCRIPTION FACTORS BRN-3A..." IN MOLECULAR AND CELLULAR BIOLOGY, FEB. 1998, VOL. 18, NO. 2, P. 1029-1041.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 2877	Application Number 10/791,017
		Applicant(s) OBENDORF	
		Filing Date 03/02/2004	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
	ANNIE MALTAIS ET AL: "THE AF2 DOMAIN OF THE ORPHAN NUCLEAR RECEPTOR...", IN CANCER LETTER 183, 2002, PP. 87-94.
	NAGANARI OHKURA ET AL: "THE EWS/NOR1 FUSION GENE..." IN THE JOURNAL OF BIOLOGICAL CHEMISTRY, VOL. 277, NO. 1, ISSUE OF JANUARY 4, PP. 535-543, 2002.
	MIRA A RAO ET AL: "RANBPM, A NUCLEAR PROTEIN THAT INTERACTS..." IN THE JOURNAL OF BIOLOGICAL CHEMISTRY, VOL. 277, NO. 50, ISSUE OF DECEMBER 2002, PP. 48020-48027.
	DANIEL ROBYR, ET AL: "NUCLEAR HORMONE RECEPTOR...", IN MOLECLULAR ENDOCRINOLOGY, VOL 14, NO. 3, 2000, PP. 329-347.
	ANA ARANDA ET AL: "NUCLEAR HORMONE RECEPTORS AND GENE EXPRESSION" IN PHYSIOLOGICAL REVIEWS, VOL. 81, NO. 3, JULY 2001, PP. 1269-1304.
	M. BEATO ET AL: "STERIOD HORMONE RECEPTORS: AN UPDATE" IN HUMAN REPRODUCTION UPDATE 2000, VOL. 6, NO. 3, PP. 225-236.
	DAVID J. MANGELSDORF: "THE RXR HETERODIMERS..." IN CELL, VOL. 83, DECEMBER 15, 1995, PP. 841-850.
	A.O. BRINKMANN ET AL: "MECHANISM OF ANDROGEN RECEPTOR..." IN JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY 69, 1999, PP. 307-313.
	OLIVIER DELATTRE ET AL: "GENE FUSION WITH AN ETS DNA..." IN LETTERS TO NATURE, VOL. 359, SEPTMBER 10, 1992, PP. 162-165.
	JESSICA ZUCMAN ET AL: "EWS AND ATF-1 GENE FUSION..." IN NATURE GENETICS VOL. 4, AUGUST 1993, PP. 341-345.
	WILLIAM L. GERALD ET AL: "CHARACTERIZATION OF THE GENOMIC BEAKPOINT..." IN PROC. NATL. ACAD. SCL USA, VOL. 92, FEBRUARY 1995, PP. 1028-1032.
	YVES LABELLE ET AL: "ONCOGENIC COVERSON OF A NOVEL ORPHAN..." IN HUMAN MOLECULAR GENETICS, VOL. 4, NO. 12, 1995, PP. 2219-2226.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 2877		Application Number 10/791,017	
		Applicant(s) OBENDORF			
		Filing Date 03/02/2004		Group Art Unit	
*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>				
	TAKATOSHI OHNO ET AL: "THE EWS GENE, INVOLVED IN EWING FAMILY..." IN ONCOGENE 1994, 9, PP. 3087-3097.				
	THOMAS MELT ET AL: "CHARACTERIZATION OF A NEW BRAN-SPECIFIC..." IN EUR. J. BIOCHEM. 268, 2001, PP. 3483-3489.				
	NEIL J. MCKENNA ET AL: "NUCLEAR RECEPTOR COREGULATORS..." IN ENDOCRINE REVIEWS 20(3), 1999, PP. 321-344.				
	XUI FEN DING ET AL: "NUCLEAR RECEPTOR-BINDING SITES OF..." IN MOLECULAR ENDOCRINOLOGY, 1998, PP. 302-313.				
EXAMINER		DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					